EFFECT OF IBANDRONATE ON RISKS FOR VERTEBRAL AND NONVERTEBRAL FRACTURES IN POSTMENOPAUSALOSTEOPOROSIS (A REVIEW OF CLINICAL TRIALS)

The paper presents data of a large number of clinical trials meeting the principles of evidence-based medicines, which have dealt with the evaluation of the efficacy of ibandronate in postmenopausal osteoporosis (OP). The administration of its registered formulations (150 mg weekly oral and 3 mg quarterly intravenous) is shown to reduce the risk of both vertebral and nonvertebral fractures, including proximal femoral fractures. It is emphasized that adequate patient adherence to antiosteopotic therapy to achieve an acceptable annual cumulative dose is one of the most important goals of effective therapy for O